-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Isatuximab in T-Cell Lymphomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Isatuximab in T-Cell Lymphomas report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Isatuximab in T-Cell Lymphomas Drug Details: Isatuximab (Sarclisa) is a monoclonal antibody...
-
Product Insights
Atypical Teratoid Rhabdoid Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Teratoid Rhabdoid Tumor - Drugs In Development, 2023’, provides an overview of the Atypical Teratoid Rhabdoid Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Teratoid Rhabdoid Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Botulism – Drugs In Development, 2023
Global Markets Direct’s, ‘Botulism - Drugs In Development, 2023’, provides an overview of the Botulism pipeline landscape. The report provides comprehensive information on the therapeutics under development for Botulism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Monkeypox – Drugs In Development, 2023
Global Markets Direct’s, ‘Monkeypox - Drugs In Development, 2023’, provides an overview of the Monkeypox pipeline landscape. The report provides comprehensive information on the therapeutics under development for Monkeypox, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Zika Virus Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Zika Virus Infections - Drugs In Development, 2023’, provides an overview of the Zika Virus Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Zika Virus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IONIS-PKKRx in Migraine
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.IONIS-PKKRx in MigraineDrug Details:IONIS-PKKRx is under development for treatment of hereditary angioedema and chronic migraine. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Fallopian Tube Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Fallopian Tube Cancer Drug Details: Azenosertib (ZNC-3) is under...
-
Product Insights
Peripheral Vascular Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Peripheral Vascular Devices Pipeline Market Report Overview Peripheral vascular devices are used to treat peripheral vascular disease (PVD). The Peripheral Vascular Devices pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Peripheral Vascular Stents ·       ...
-
Product Insights
PG&E Corp – The Nighthawk Storage 300 MW Project – California
Equip yourself with the essential tools needed to make informed and profitable decisions with our PG&E Corp - The Nighthawk Storage 300 MW Project - California report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
-
Company Profile
NightHawk Biosciences Inc – Company Profile
NightHawk Biosciences Inc (NightHawk Biosciences) formerly Heat Biologics Inc, is a leading biotechnology company specializing in the development and commercialization of advanced medical technologies and therapies. Its major commercially available product is Anthim (obiltoxaximab), an FDA-approved monoclonal antibody specifically developed for the treatment of inhalational anthrax. Anthim has received orphan drug exclusivity, highlighting its unique status in addressing this serious medical condition. It is also approved in Europe, Canada and the UK. NightHawk Biosciences is headquartered in Durham, North Carolina,...
Add to Basket